AI-powered organoid handling
Short Business Description:
Traditional drug testing is slow, expensive, and unreliable, with 90% of animal-tested drugs failing in humans. Organoids—miniature lab-grown human organs—offer a better alternative, but their use is limited by manual, inconsistent workflows. Visienco solves this with Orgadroid, an AI-powered benchtop device that automates organoid sorting with precision and scalability. Developed at CSEM, this technology ensures high-quality organoids, accelerating drug discovery, diagnostics, and personalized medicine—while reducing the need for animal testing.
Visienco AG is pioneering the future of organoid-based research with a mission to bring automation, precision, and scalability to one of the most promising technologies in life sciences. The startup is developing the Orgadroid, a compact, AI-powered benchtop device that automates the sorting of lab-grown organoids. By improving reproducibility and drastically reducing the amount of manual labor involved in organoid workflows, Visienco is enabling pharmaceutical and biotech companies to accelerate drug discovery and move toward more ethical, efficient research methods.
Organoids – miniature, functional versions of human organs grown from stem cells – have emerged as a revolutionary alternative to animal testing, with potential applications in diagnostics, toxicology, and personalized medicine. Yet despite their promise, current handling methods are labor-intensive, error-prone, and difficult to scale. Visienco addresses these bottlenecks with deep-learning-based image analysis, sterile sorting, and gentle transfer mechanisms, all integrated into a user-friendly system that fits into existing lab setups.
The Orgadroid is designed to make organoid research more consistent and accessible, helping researchers retain only the most viable samples for downstream applications. By reducing variability, waste, and cost, Visienco’s technology also supports faster development of patient-specific treatments and improves the overall reliability of preclinical testing.
With a global organoid market projected to reach $15 billion by 2031, and increasing regulatory pressure to reduce animal testing, Visienco is positioned at the heart of a transformative shift in biomedical research. The company aims to reduce manual organoid handling time by 80% and cut material waste by half by 2030. Broader goals include accelerating the adoption of automated workflows and contributing to a 30% reduction in animal testing in preclinical pipelines.
Leading Visienco is co-founder and CEO Edwige Guinet, whose multidisciplinary background in biotech and entrepreneurship drives the company’s strategic direction. Under her leadership, Visienco combines cutting-edge engineering with practical lab insight, offering a solution that meets both the scientific and operational needs of modern research.